Alvotech and Fuji Pharma Expand Partnership Adding a New Biosimilar CandidateGlobeNewsWire • 01/13/23
Alvotech Initiates Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®GlobeNewsWire • 01/11/23
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)Business Wire • 01/06/23
Update on U.S. Regulatory Status of AVT02, Alvotech's Proposed High-Concentration, Interchangeable Biosimilar to Humira®GlobeNewsWire • 12/22/22
Correction to Total Amount in Announcement About Private Placement Published 2022-12-16 09:00 GMT to headline fieldGlobeNewsWire • 12/16/22
Correction to Total Amount in Announcement About Private Placement Published 2022-12-16 09:00 GMTGlobeNewsWire • 12/16/22
Alvotech and STADA Broaden Access to Hukyndra® adalimumab biosimilar in EuropeGlobeNewsWire • 12/07/22
Nasdaq Iceland Approves the Request for Trading of Alvotech's Shares on the Main MarketGlobeNewsWire • 12/02/22
Alvotech Submits its Application for Admission of the Company's Shares to Trading on Nasdaq Iceland Main MarketGlobeNewsWire • 11/30/22
Alvotech Reports Financial Results for First Nine Months of 2022 And Provides Business UpdateGlobeNewsWire • 11/16/22
Alvotech Announces Australian Marketing Authorization for AVT02, a Biosimilar to Humira®GlobeNewsWire • 11/14/22
Alvotech to Present Switching Study Data for AVT02, a Proposed Biosimilar to Humira®, at 2022 American College of Rheumatology ConferenceGlobeNewsWire • 11/10/22
Alvotech to Report First Nine Months Financial Results on November 15, 2022 and Host Business Update Conference Call at 8:00 am ET on November 16, 2022GlobeNewsWire • 10/27/22
Alvotech to Participate in Upcoming Jefferies London Healthcare Conference in NovemberGlobeNewsWire • 10/26/22
Alvotech and JAMP Pharma Expand Exclusive Partnership Adding Two Biosimilar Candidates for Canadian Market, Bringing New Options for Patients in Specialty CareGlobeNewsWire • 10/19/22
Alvotech's Partner Submits Application for Marketing Approval of First Biosimilar Candidate in JapanGlobeNewsWire • 10/17/22
Alvotech and STADA Increase Access to Adalimumab for Patients in Switzerland with the Launch of Hukyndra®GlobeNewsWire • 09/22/22